Gynecologic oncology最新文献

{"title":"Society of Gynecologic Oncology Annual Meeting Special Issue","authors":"","doi":"10.1016/j.ygyno.2026.04.001","DOIUrl":"10.1016/j.ygyno.2026.04.001","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"207 ","pages":"Page 1"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147685639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of cadonilimab combined with chemotherapy as first-line treatment for primary advanced or recurrent endometrial cancer: An interim analysis of a prospective, single-arm, open-label phase II trial","authors":"Bin Liu ,&nbsp;Jian Chen ,&nbsp;Lijun Chen ,&nbsp;Xiaoxiang Chen ,&nbsp;Yanhong Zhuo ,&nbsp;Linlin Yang ,&nbsp;Yuzhi Li ,&nbsp;Jie Lin ,&nbsp;Xinye Guo ,&nbsp;Yingtao Lin ,&nbsp;Tongyu Liu ,&nbsp;Jianping Zou ,&nbsp;Yu Jiang ,&nbsp;Yang Sun","doi":"10.1016/j.ygyno.2026.03.014","DOIUrl":"10.1016/j.ygyno.2026.03.014","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the interim efficacy and safety of cadonilimab, a PD-1/CTLA-4 bispecific antibody, in combination with platinum-based chemotherapy as first-line treatment for patients with primary advanced or recurrent endometrial cancer (EC), with exploratory analyses by molecular subgroups.</div></div><div><h3>Methods</h3><div>This investigator-initiated, multicenter, open-label, single-arm phase II trial enrolled women aged 18–75 years with histologically confirmed FIGO stage III/IV or recurrent EC. Patients received cadonilimab (10 mg/kg intravenously every 3 weeks) combined with platinum-based chemotherapy, followed by cadonilimab maintenance. The primary endpoint was objective response rate (ORR) assessed per RECIST v1.1. Secondary endpoints included disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. Exploratory analyses were performed according to PD-L1 expression, mismatch repair (MMR) status, and molecular subtype. This interim analysis was conducted after 27 efficacy-evaluable patients reached the predefined PFS milestone.</div></div><div><h3>Results</h3><div>Among 27 patients, ORR was 74.1% (95% CI, 55.6%–87.3%), including one complete response (3.7%) and 19 partial responses (70.4%), with a DCR of 96.3%. Median time to response was 2.8 months, and median DoR was 17.8 months (95% CI, 8.8–not estimable). Median PFS was 10.5 months (95% CI, 8.2–not estimable), with a 12-month PFS rate of 49.6%. Median OS was not reached; the 12-month OS rate was 90.2%. ORR was generally consistent across subgroups, while patients with dMMR tumors showed a lower risk of disease progression compared with those with pMMR tumors. Treatment-related adverse events occurred in 77.8% of patients, predominantly grade 1–2; grade ≥ 3 events occurred in 18.5%, with no treatment-related deaths.</div></div><div><h3>Conclusions</h3><div>Cadonilimab combined with chemotherapy demonstrated clinically meaningful activity and manageable safety as first-line treatment for advanced or recurrent EC, supporting further investigation, particularly in molecularly defined populations.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"207 ","pages":"Pages 14-22"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147685686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGO 2026 annual meeting: Honors and Recognitions for Authors and Reviewers for 2025-2026","authors":"","doi":"10.1016/j.ygyno.2026.04.002","DOIUrl":"10.1016/j.ygyno.2026.04.002","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"207 ","pages":"Page 2"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147685640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study","authors":"Els Van Nieuwenhuysen ,&nbsp;Ignace Vergote ,&nbsp;Leslie M. Randall ,&nbsp;Jacqueline Tromp ,&nbsp;Domenica Lorusso ,&nbsp;Roisin E. O’Cearbhaill ,&nbsp;Ingrid Boere ,&nbsp;Carmela Pisano ,&nbsp;Luis Manso Sanchez ,&nbsp;Susana Banerjee ,&nbsp;Dearbhaile C. Collins ,&nbsp;Michal Zikán ,&nbsp;Cara Mathews ,&nbsp;Jan Kümmel ,&nbsp;Bohuslav Melichar ,&nbsp;Amanda L. Jackson ,&nbsp;Kristine Madsen ,&nbsp;Christine Gennigens ,&nbsp;Nelleke Ottevanger ,&nbsp;Sharad Ghamande ,&nbsp;Bradley J. Monk","doi":"10.1016/j.ygyno.2026.02.008","DOIUrl":"10.1016/j.ygyno.2026.02.008","url":null,"abstract":"<div><h3>Objective</h3><div>Treatment options for recurrent or metastatic cervical cancer (r/mCC) remain limited. We evaluated the efficacy and safety of tisotumab vedotin (TV)–based combinations with standard agents in first-line (1L) and previously treated (second-line or later [2L+]) settings in r/mCC.</div></div><div><h3>Methods</h3><div>innovaTV 205/ENGOT-cx8/GOG-3024 (<span><span>NCT03786081</span><svg><path></path></svg></span>) was a multicenter, open-label phase 1b/2 study, which included dose-expansion arms of 1L TV + carboplatin (arm D), 1L/2L+ TV + pembrolizumab (arms E/F), and 1L TV + carboplatin + pembrolizumab ± bevacizumab (arm H). The primary endpoint was investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors v1.1. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs).</div></div><div><h3>Results</h3><div>As of October 15, 2025, 139 patients were enrolled in dose-expansion arms D (<em>n</em> = 33), E (n = 33), F (<em>n</em> = 35), and H (<em>n</em> = 38). Confirmed ORR (median DOR) was 54.5% (8.6 months), 40.6% (not reached), 35.3% (18.2 months), and 65.8% (13.3 months) in arms D–F and H, respectively. Median PFS was 6.9, 5.3, 5.6, and 10.6 months; median OS was 25.5, 30.7, 15.3, and 28.0 months. Grade ≥ 3 AEs related to any treatment component occurred in 72.7%, 45.5%, 48.6%, and 86.8% of patients; AEs leading to TV discontinuation occurred in 24.2%, 24.2%, 34.3%, and 55.3% of patients in arms D–F and H, respectively.</div></div><div><h3>Conclusion</h3><div>With ≥ 5 years of follow-up, TV doublet combinations demonstrated durable activity consistent with previous findings and encouraging long-term OS in 1L and 2L+ r/mCC, with no new safety signals. The 1L TV-based triplet/quadruplet regimen showed meaningful antitumor activity with expected toxicity.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"207 ","pages":"Pages 3-13"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147685641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Industry payments to U.S. gynecologic oncologists: Gender, geographic, and therapeutic trends","authors":"Gabriel Levin ,&nbsp;Lucy Gilbert ,&nbsp;Robert L. Coleman ,&nbsp;Raanan Meyer ,&nbsp;Reitan Ribeiro ,&nbsp;Bradley J. Monk","doi":"10.1016/j.ygyno.2026.02.002","DOIUrl":"10.1016/j.ygyno.2026.02.002","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate gender- and geography-based differences in industry payments to U.S. gynecologic oncologists and to characterize temporal trends in payments across therapeutic classes.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional analysis of the Centers for Medicare &amp; Medicaid Services Open Payments database from 2018 to 2024. All physicians listed as gynecologic oncologists were included, with general payments aggregated per physician. Payments were analyzed by physician gender, geographic region, and state. Drug-related payments were mapped to therapeutic classes relevant to gynecologic oncology, and temporal trends were examined descriptively.</div></div><div><h3>Results</h3><div>Overall 75,382 industry payments totaling $33.4 million were made to 2063 gynecologic oncologists (55.9% females, and 44.1% males). Males were overrepresented among the top 100 total earners (74% vs. 26%; <em>p</em> &lt; .001). Compared with females, males received higher median total payments ($863 vs. $312), a greater number of payments (12 vs. 6), and higher mean single payments ($64 vs. $49; all <em>p</em> &lt; .001). Regionally, the South accrued the highest total payments ($11.3 M), whereas mean single payments were highest in the West ($390). Drugs and biologics comprised 63.5% of all payments, dominated by PARP inhibitors, which peaked in 2019 and declined thereafter, while payments related to antibody–drug conjugates, immune checkpoint inhibitors, and tyrosine kinase inhibitors increased steadily and constituted the majority by 2024.</div></div><div><h3>Conclusions</h3><div>Industry payments to gynecologic oncologists demonstrate persistent gender and geographic diffrences and reflect evolving therapeutic priorities within the field. Increased transparency and proactive efforts are needed to promote balanced access to industry-sponsored opportunities as novel treatments emerge.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"207 ","pages":"Pages 60-66"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147685690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ACT-ON: Assisted cascade testing via outreach and navigation – Real-world experience with clinician-facilitated cascade testing","authors":"Emily S. Epstein ,&nbsp;Michelle Primiano ,&nbsp;Amanda Laterza Ozarowski ,&nbsp;Tina Karimaghaie ,&nbsp;Max Kirby ,&nbsp;Steve Lopez ,&nbsp;Jose Alejandro Rauh-Hain ,&nbsp;Roni Wilke ,&nbsp;Haley A. Moss ,&nbsp;Jesse Brewer ,&nbsp;Sarah R. Levi ,&nbsp;Taylor LaRosa ,&nbsp;Alissa Kalyan ,&nbsp;Ashley Llenas ,&nbsp;Susan Marchal ,&nbsp;Li Bing Song ,&nbsp;Muhammad Danyal Ahsan ,&nbsp;Ravi N. Sharaf ,&nbsp;Melissa K. Frey","doi":"10.1016/j.ygyno.2026.01.775","DOIUrl":"10.1016/j.ygyno.2026.01.775","url":null,"abstract":"<div><h3>Objectives</h3><div>Cascade genetic testing is a pragmatic, high-impact strategy for cancer prevention; however, under the current patient-mediated model, only one-third of relatives complete testing. Clinician-facilitated cascade testing represents a promising alternative, though questions remain regarding scalability and effectiveness in real-world settings. We aimed to evaluate the outcomes of a real-world, clinician-facilitated cascade testing program.</div></div><div><h3>Methods</h3><div>We implemented a clinician-facilitated cascade testing program to contact, educate, and facilitate genetic testing for at-risk relatives. Probands from gynecologic oncology and cancer genetics clinics provided consent for direct relative contact for education on cascade testing and assistance with access to local or direct-to-consumer genetic counseling and testing services. Relatives were recontacted at six months for follow-up.</div></div><div><h3>Results</h3><div>From May 2023 to July 2025, 103 probands (median age 40 years; 87% female) identified 139 at-risk relatives. Of these, 91 (65%) relatives were successfully contacted and educated about the familial pathogenic variant (median age 45 years; 59% female) and 80 (88%) requested assistance with cascade testing. At six-month follow-up, 41 (77%) of relatives reached had completed genetic testing. On a follow-up survey, 100% of respondents reported that navigation support was integral to accessing testing and 68% indicated they would have been unlikely to pursue testing without clinician support.</div></div><div><h3>Conclusions</h3><div>In a real-world setting, clinician-facilitated cascade testing successfully contacted two-thirds of at-risk relatives, the majority of whom requested assistance with testing. These findings demonstrate the potential of clinician-facilitated navigation to overcome limitations of patient-mediated approaches and offer a scalable, patient-centered strategy for cancer prevention.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"207 ","pages":"Pages 38-46"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147685689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanded subtype testing for circulating tumor HPV DNA reliably detects the presence of advanced-stage cervical cancer","authors":"Kersten Rothnie ,&nbsp;Emilie Tristano ,&nbsp;Mariuxi Diaz-Rodriguez ,&nbsp;Olga Filippova ,&nbsp;Gizelka David-West ,&nbsp;Joan Tymon-Rosario ,&nbsp;Jill Whyte ,&nbsp;Marina Frimer ,&nbsp;Tung Ming Leung ,&nbsp;Fidel Valea ,&nbsp;Jeannine Villella ,&nbsp;Elena Pereira","doi":"10.1016/j.ygyno.2026.02.013","DOIUrl":"10.1016/j.ygyno.2026.02.013","url":null,"abstract":"<div><h3>Objectives</h3><div>To demonstrate the detection of circulating human papillomavirus (HPV) DNA fragments can serve as a biomarker for presence of tumor and provide a universal, non-invasive tool for monitoring treatment response in HPV-related cervical cancers (CC).</div></div><div><h3>Methods</h3><div>A multi-site prospective study of HPV-positive high-grade cervical dysplasia (CIN2/3) and CC was conducted. Serum samples were collected pre-, during, and post-treatment. NavDx® (Naveris,Inc) digital droplet polymerase chain reaction testing was used to detect tumor tissue modified viral (TTMV)-HPV DNA. The expanded panel included 14 HPV subtypes. Sensitivity and specificity were calculated for the pre-treatment Score only. Scores were quantified for on-treatment timepoints and trends were compared against treatment response.</div></div><div><h3>Results</h3><div>80 patients were included in the analysis: 46 (57.5%) CC, 26 (32.5%) CIN2/3, 8 (10.0%) benign. TTMV-HPV DNA was undetectable in all CIN 2/3 and benign cases. For CC, 38 (82.6%) had primary disease and 8 (17.4%) recurrent. For primary CC, 28 (73.7%) had stage I/II and 10 (26.3%) stage III/IV. Specificity for TTMV-HPV DNA for CC detection was 100% (95% CI: 89.7%–100.0%) for all stages. Sensitivity was 39.2% (95% CI: 21.5–59.4%) for stage I/II, 90% (95% CI: 55.5–99.7%) for stage III/IV, and 62.5% (95% CI: 24.4–91.48%) at recurrence. Disease progression/persistence occurred in 7 patients with corresponding increased Scores.</div></div><div><h3>Conclusions</h3><div>TTMV-HPV DNA is a sensitive and specific biomarker for advanced CC, with Scores dynamically corresponding to treatment response, and has the potential to serve an unmet need as a universal biomarker for patients with HPV-related CC.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"207 ","pages":"Pages 47-52"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147685693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of a community-centered intervention on knowledge, confidence, and attitudes toward clinical trials: A pilot survey study","authors":"Oriana Krivenko ,&nbsp;Nicole Diaz ,&nbsp;Kimberly Richardson ,&nbsp;Daniel Antonio ,&nbsp;Dario Roque","doi":"10.1016/j.ygyno.2026.02.015","DOIUrl":"10.1016/j.ygyno.2026.02.015","url":null,"abstract":"<div><h3>Background</h3><div>Cancer clinical trials are essential to advancing the management of gynecologic cancers; however, women of color remain underrepresented despite experiencing disproportionately poor outcomes. Barriers to enrollment include skepticism, limited awareness, inadequate referral processes, and failure to offer trial participation. Community-based partnerships may help address these gaps.</div></div><div><h3>Methods</h3><div>We partnered with two Chicago-based community-based organizations serving African American and Hispanic women to co-develop a culturally tailored educational curriculum focused on gynecologic oncology clinical trials. Community leaders contributed to curriculum design to ensure cultural relevance. Anonymous pre- and post-session surveys assessed clinical trial knowledge, communication and decision self-efficacy, access and navigation, and trust-related attitudes using 10 Likert-scale items grouped into four thematic domains. Because responses were unlinked, pre- and post-groups were analyzed as independent samples using Mann–Whitney <em>U</em> tests with false discovery rate correction. Effect sizes were calculated using rank-biserial correlations.</div></div><div><h3>Results</h3><div>Seventy-eight participants were included (51 African American, 27 Hispanic). Across the full cohort, the intervention was associated with significant improvements in clinical trial knowledge, communication and decision self-efficacy, and access and navigation (<em>r</em> = 0.28–0.32, all <em>p</em> &lt; 0.001), with smaller, non-significant effects observed for trust-related attitudes. Among African American participants, eight of ten survey items demonstrated statistically significant post-intervention improvements, with small-to-moderate effect sizes (<em>r</em> = 0.28–0.47). Among Hispanic participants, effect sizes were consistently positive (<em>r</em> = 0.06–0.31), particularly for knowledge and access domains, but did not reach statistical significance due to limited power.</div></div><div><h3>Conclusion</h3><div>A community-engaged educational intervention was associated with improved clinical trial knowledge and self-efficacy among minoritized women, supporting further evaluation of community-partnered strategies to promote equitable clinical trial engagement.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"207 ","pages":"Pages 53-59"},"PeriodicalIF":4.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147685694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eco-responsible and rational interval debulking surgery for high-grade ovarian carcinomas: An observational, ambispective cohort study","authors":"Sarah Hodent ,&nbsp;Naoual Bakrin ,&nbsp;Pascal Rousset ,&nbsp;Vahan Kepenekian ,&nbsp;Witold Gertych ,&nbsp;Pierre Descargues ,&nbsp;Laurent Villeneuve ,&nbsp;Mojgan Devouassoux-Shisheboran ,&nbsp;Marion Favretto ,&nbsp;Benoit You ,&nbsp;Pierre-Adrien Bolze ,&nbsp;Lucie Gaillot-Durand ,&nbsp;Jonathan Lopez ,&nbsp;Olivier Glehen ,&nbsp;Alexis Trecourt","doi":"10.1016/j.ygyno.2026.01.771","DOIUrl":"10.1016/j.ygyno.2026.01.771","url":null,"abstract":"<div><h3>Background</h3><div>Since the workload generated by interval debulking surgeries (IDS) for advanced high-grade tubo-ovarian carcinomas is high in the surgical pathology department (SPD), we aimed to assess the impacts of implementing an eco-responsible protocol to manage specimens from IDS.</div></div><div><h3>Methods</h3><div>The protocol (ECO-IDS) defined the specimens to send to the SPD and the sampling strategy during gross examination. Twenty patients were prospectively included (post-ECO-IDS group). A retrospective cohort of 20 patients, who did not benefit from the protocol, was built (pre-ECO-IDS group). Criteria compared were: the number of jars sent/paraffin blocks prepared, pathology procedures' carbon footprint, financial cost of specimen processing, time for pathology report validation, and chemotherapy response score (CRS). Next-generation sequencing (NGS) was performed to ensure the feasibility of molecular techniques on the post-ECO-IDS samples.</div></div><div><h3>Results</h3><div>The median number of jars sent per patient was 4 (post-ECO-IDS group) <em>versus</em> 14 (pre-ECO-IDS group; <em>p</em> &lt; 0.0001). The median number of paraffin blocks prepared per patient was 12.5 (post-ECO-IDS group) <em>versus</em> 38 (pre-ECO-IDS group; <em>p</em> &lt; 0.0001). The median carbon footprint per patient was 8.6 KgCO₂eq (post-ECO-IDS group) <em>versus</em> 24.1 KgCO₂eq (pre-ECO-IDS group; p &lt; 0.0001). The median financial cost was €25.5 (post-ECO-IDS group) <em>versus</em> €57.9 (pre-ECO-IDS group; p &lt; 0.0001). The mean time for pathology report validation was 7.5 days (post-ECO-IDS group) <em>versus</em> 10 days (pre-ECO-IDS group; <em>p</em> = 0.0131). There was no difference in CRS between both groups. NGS identified <em>TP53</em> variants in 19/20 (95%) tumors.</div></div><div><h3>Conclusion</h3><div>Our protocol reduced environmental impacts, financial costs, and time to pathology report validation, without compromising the quality/safety of histopathology results.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"206 ","pages":"Pages 32-38"},"PeriodicalIF":4.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TOC","authors":"","doi":"10.1016/S0090-8258(26)00839-5","DOIUrl":"10.1016/S0090-8258(26)00839-5","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"206 ","pages":"Pages iv-v"},"PeriodicalIF":4.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147539201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}